The market size of cardiovascular drugs will reach 270.106 billion in 2016

China's cardiovascular drug market size in 2015 was RMB256.201 billion, up 8.4% YoY (by retail price of the drug market, the same between 2015) (see the five key data on cardiovascular system drug use (with TOP20 brand for details); With the steady growth of sales of cardiovascular drugs year by year and the maturation of the market, some varieties stand out in the fierce market competition - in 2015, the number of cardiovascular drugs entering the 3 billion yuan club has reached 15, of which the highest sales of more than 8 billion yuan.
1, injection thrombosis
subject to medical insurance control fees and tender price limits and equivalent price limit policy, injection thrombosis sales gradually weakened. In 2015, the market sales scale of domestic injection thrombosis (based on the retail price of the market, taking into account the situation of terminal pressure) was RMB 8,035 million, a decrease of 4.32% YoY. From the terminal situation, in addition to retail pharmacies and city-grade hospitals, injection thrombosis in other terminals showed a downward trend.
It is worth mentioning that earlier this year the CFDA issued the Notice on revising the instructions for thrombosis injections and thrombosis injections, requiring adverse reactions to be noted in the instructions for two large varieties of Chinese medicine, thrombosis injections and thrombosis injections. From this point of view, the market environment for thrombosis for injection may be further tightened.
2, atovastatin calcium tablets
in blood lipid-lowering drugs, statin performance has been quite prominent. Among them, atovastatin calcium as a monument in the history of the development of blood lipid drugs, accounting for half of the blood lipid drug market. Pfizer, the original product of Atovastatin, went public worldwide in 1997 and became the first prescription drug in history to sell more than $10 billion a year in 2004, maintaining a level of $10 billion for seven consecutive years, peaking at $12.886 billion.
In recent years, the market for attovastatin has been declining due to the erosion of statins such as risovastatin and simvastatin, but its position will not be easily shaken until a new generation of blood lipid drugs is widely used in clinical practice. In 2015, Lipto still ranked first in the list of blood lipid-lowering chemicals with a score of 5.647 billion yuan. In addition, the domestic drug performance is better is Beijing Jialin Pharmaceuticals' Ale and Henan Tianfang Pharmaceuticals' Yujia.
3, Danhong injection
as early as 2011, the exclusive patented pharmaceutical product Danhong injection for step pharmaceutical has brought 3 billion yuan of sales performance, known as the domestic Chinese medicine injection in the "exclusive king of single products." Since then, the market sales of Danhong injections have been rising, with sales of 5.468 billion yuan in 2015.
, as a Chinese medicine injection, Danhong injection is also difficult to avoid the pressure of medical insurance charges, adverse drug reactions, the growth trend has slowed down. In July, the IPO of Step Pharmaceuticals, which has struggled on the road to the market for years, was first approved, but the relative concentration of its products was a cause for concern (brain heart capsules, steady-heart particles and dan red injections accounted for a significant proportion of company sales). Step Pharmaceuticals also admitted that the production and sales of any of the products, if there is a large change, may have a greater impact on the company's operations.
4, injection with compound coenzyme
injection compound coenzyme is the exclusive variety of the pharmaceutical industry, listed for many years has been strong prices, few competitors. In 2015, sales of injection compound coenzymes were 4.625 billion yuan. Sample hospital-related sales data analysis shows that the sales of this variety has been accounted for about 70% of the total sales of the drug industry, from the current point of view, the drug industry also has a major hidden danger.
Since last year, injection compound coenzyme has been included in the list of auxiliary drugs or key drugs monitoring, in January this year Anhui more clearly it can not be included in the clinical path form, restrictions on the use of measures further upgraded. According to the analysis of securities institutions, the market for injection compound coenzyme is mostly confined to the three-level hospitals in large and medium-sized cities, with greater pressure and an estimated growth rate of about -10%.
5, blood-sucking injection
the exclusive variety of blood-sucking injection is the prevention and treatment of cerebral thrombosis and cerebrovascular diseases such as cerebrovascular diseases, is to fill the national animal Chinese medicine compound injection blank varieties, with a number of national invention patents. Sales in 2015 were 4.519 billion yuan.
2015, you can't help pharmaceutical company's 6.5 billion shell Jiuzhitang successfully listed. However, the industry has greater doubts about the development of Jiuzhitang and Youfu: the former varieties are relatively dispersed, competitive products are not many; Obviously, in the increasingly strict pharmaceutical policy situation, you bo pharmaceutical research and development of new drugs or need to keep up in time.
6, benzodialycerine chloride tablets
ammonia chloride is a calcium ion antagonist, the original manufacturer for Pfizer. In 1987, benzodiacycline chloride tablets were listed in the United States under the trade name "Live Joy", and clinical trials have shown that their long-term application to patients with coronary heart disease can significantly reduce cardiovascular events, thus becoming a leader in this class of drugs.
recent years, angiotensin II. the blocker (ARB) has gradually become the darling of hypertension drugs, but in the domestic market, calcium ion channel antagonists (CCB) is still in full force. In 2015, Pfizer's benzodiacycline chloride tablets continued to boast a market performance of 3.877 billion yuan. Obviously, although the patent has long expired, there are Suzhou Dongrui Pharmaceuticals, China Resources Seko and other enterprises to produce the product, but it is still difficult to shake the share of the original research drugs.
7, cerebral heart pass capsule
steps long pharmaceutical brain heart pass capsule entered the market in 1993, for cerebral infarction, coronary heart disease angina and other diseases have significant efficacy, is listed as the national secondary Chinese medicine protection varieties, at the same time has been included in the national medical insurance directory and the national base drug catalog, in urban communities and township hospitals market accounted for a relatively high. In 2015, 5,088 million capsules were shipped, with a market size of 3.843 billion yuan. As the main variety of cardiovascular medicine, the market size of Chinese medicine injection is expected to be further improved at a time when the safety of Chinese medicine injections has been affected.
8, Malay acid cinnamon zeit injection
In 1974, the French company Sanofi-Avente developed a new generation of cinnamon-type drug Malay acid cinnamon zeit in France, rapidly developed into a cardiovascular first-line drug. In April 2002, Beijing four-ring medicine Malay acid cinnamon zitt injection (Clint Australia) was approved for listing, after a long period of exclusive market, until 2015 the protection period of new drugs ended, competing drugs have been listed, the number of declared enterprises gradually increased, only to break this situation. By the end of 2015, Fujian Jinshan Biopharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd. Malay acid cinnamon Cinzit injections have been approved for listing. Judging by the sales of 3.803 billion yuan in 2015, it has not yet been significantly affected. But as the competition grows, its market share will gradually be split.
9, nitrobenzene flat control tablets
nitrobenzene is a cardiovascular system calcium antagonist, is the FDA approved in 1981 new molecular entities, in 1989 its controlled release agent was approved, is a classic old drug, has a considerable clinical application base. In China, although there have been a number of slow-control release preparations on the market, but because it is not yet mature in the research of innovative dosage forms, Bayer's nitrobenzene flat-control release tablets (Bay Xintong) still occupy the vast majority of the market, and sales steadily increased year by year. In 2015, Baixintong continued to top the list of similar products with a market performance of 3.777 billion yuan. Among the domestic products, Qingdao Huanghai Pharmaceuticals'Zhangda, Shanghai Hyundai Pharmaceuticals' Xingaida also performed better.
10, forefront of the injection
At present, the domestic manufacturers of the forefront of the Terr has Beijing Ted Pharmaceuticals, Ha Pharmaceutical Group bioengineering, Benxi Leilong Pharmaceuticals, Xi'an Libang Pharmaceuticals, Chongqing Pharmaceutical Friends and so on. Among them, Beijing Ted Pharmaceutical's Kai time although maintain a large advantage, but its nearly three years of the market has gradually become tired. In 2015, Kaishi continued to rank first in the market with a score of 3.625 billion yuan, but its 2015 was a difficult year, with the impact of similar drugs at home and imports from abroad, as well as the challenges of bidding for price reductions, rebates, and being included in the list of complementary drugs in some provinces and cities. Sales are still expected to be affected in 2016.
11, Dansan Kawakubo injection
Although there has been controversy, the current largest sales of Chinese medicine is still Chinese medicine injection. The main components of dansankawa's injection are Chinese medicine extracts dansan and hydrochloric acid, after many years of market development and application, in the domestic cardiovascular drug market has been in the forefront. Cornbelt's $1 billion holding of Bate Pharmaceuticals, Dansan Kawakawa's injections are a credit. In 2015, the market size of its Dansan Kawakubo injection was 3.614 billion yuan, with a marked slowdown in growth. At the same time, the injection of Dansan Kawakubo is also difficult to escape the fate of being included in the key monitoring scope of auxiliary drug use. As catalogues were introduced at the end of 2015, the impact on the 2015 revenue of the products was not outstanding, but sales trends in 2016 may require new engines.
12, compound Dansan drop pills
Tiansli compound dansin drop pills, is China's first case of the U.S. FDA's compound Chinese medicine. Its market has maintained a relatively stable development, over the years has been in the same varieties far ahead, sales in 2015 reached 3.447 billion yuan. On March 16 this year, the compound dansin pill completed Phase III. phase clinical trial work ahead of schedule at the FDA and entered the COV (Clinical Center Closure Visit) phase. If passed, it is expected to become the first successful U.S. FDA compound chinese medicine. As a result, the variety will not only be available for sale in the United States, but its position and market performance in the local market will also be greatly enhanced.
13, Pythatan capsule
python is an antagonist of angiotensin II. As one of the world's first species to be marketed in the Shatan family and has achieved billions of dollars, the clinical application of satan is very widespread. Among them, Novarma Pharmaceuticals' Pythatan capsule (Devon) is the best in this category. In 2015, Devon's sales were 3.343 billion yuan. Notably, in 2015, the FDA approved Novarma's anti-thoratrex drug EntrestoTM (Opachula/Pysatan) tablets for the treatment of reduced blood-shooting scores. Once the drug is approved to enter our country, it will certainly impact the market of our country and even the whole angiotensin II subject antagonist drug market.
14, Dansan Ketone II.A Sodium Sulfonate Injection
Dansan Ketone II.A Sodium Sulfonate Injection is a chemical pharmaceutical preparation of dansan active ingredient monosomy derivatives, is the Shanghai Pharmaceutical Group's Shanghai First Biochemical Pharmaceutical Co., Ltd. national exclusive varieties. The drug is mainly used in coronary heart disease, angina, myocardial infarction auxiliary treatment, the main group of patients for the elderly, is one of the mainstream varieties of cardiovascular clinical drugs. In 2015, the market sales of sodium sulfonate injection reached 3.225 billion yuan, based on its high efficacy and safety recognition, it is expected to continue to maintain a relatively stable growth in 2016.
15, benzoic acid L-Chloride tablets
From recent years of data, benzoic acid L-Chloride tablets (Schhuida) has maintained a relatively stable growth. In 2015, Shi Huida's sales exceeded the 3 billion mark for the first time, reaching 3,075 million yuan. Under the background of calcium ion channel antagonist (CCB) and angiotensin II. subject blocker (ARB), the presence of benzoic acid lysolamine chloride tablets has increased the industry's confidence in domestic drugs - at the end of the 20th century, after the successful development of L-Achloride in China. In 1999, Shi Huida Pharmaceutical Group (Jilin) benzoate L-ammonia chloride was approved for listing, and a number of enterprises have entered the field. As a left-handed isomer of ammonia chloride, L-chlorodepin has the characteristics of good efficacy, small adverse reactions and small dosing, and has a strong growth in the differentiated drug species of antihypertensive in China. (New Kangjie)